High dose frusemide in the treatment of hypertension in chronic renal insufficiency and of terminal renal failure
Frusemide in doses up to 2000 mg per day orally has proved a useful adjuvant therapy for resistant hypertension in patients with chronic renal failure, A worth-while diuresis is uncommon if the creatinine clearance is below 2 ml per minute but a useful, though often temporary, effect is obtained in...
Gespeichert in:
Veröffentlicht in: | Postgraduate medical journal 1971-04, Vol.47 (Suppl), p.45 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | Suppl |
container_start_page | 45 |
container_title | Postgraduate medical journal |
container_volume | 47 |
creator | Rastogi, S. P. Volans, G. Elliott, R. W. Eccleston, D. W. Ashcroft, R. Webster, D. Kerr, D. N. S. |
description | Frusemide in doses up to 2000 mg per day orally has proved a useful adjuvant therapy for resistant hypertension in patients with chronic renal failure, A worth-while diuresis is uncommon if the creatinine clearance is below 2 ml per minute but a useful, though often temporary, effect is obtained in the range 2 to 4 ml/min. Above this level of renal function the extent of the diuresis is not reliably predictable from the creatinine clearance but must be found individually for each patient. The dose should be increased with particular caution in patients with chronic pyelonephritis and a creatinine clearance above 10 ml per minute. Side-effects, other than those of excessive diuresis, have been uncommon. Hypokalaemia is readily prevented by the administration of potassium supplements and spironolactone. A rise in plasma urate is common but not usually dramatic and it has not precipitated secondary gout in our experience to date. |
doi_str_mv | 10.1136/postgradmedj-47-suppl-45 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_1770799243</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3972196001</sourcerecordid><originalsourceid>FETCH-LOGICAL-b316t-aeb22300ce914721440011e0e392b86a42878ad3324f0840667efbc166c7a2943</originalsourceid><addsrcrecordid>eNpNkUtv2zAQhIkiReIm_QkBCOTMli9xpWNiJHHRJD3kcSUoaRXTsR4mKSD-95Vrw-hpgZ1vF4MZQqjgP4RQ5ufQx_QeXN1ivWIaWByHYc109oXMhDYF45CZEzLjXEmWaVBn5FuMK86FAi1OyWmWQQEgZmSz8O9LWvcRaRPGiK2vkfqOpiXSFNClFrtE-4YutwOGhF30fbcDqmXoO1_RgJ1bT4s4No2vPHbVlrqu3p0kDK3fqXumcX49BrwgXxu3jvj9MM_J693ty3zBHv7c_5pfP7BSCZOYw1JKxXmFhdAghdaTe4EcVSHL3Dgtc8hdrZTUDc81NwawKSthTAVOFlqdk6v93yH0mxFjsqt-DJORaAUAh6KQWk3U5YEayylMOwTfurC1h4Amne11HxN-HmUXPqwBBZl9epvb58W9eOOPN_b3xKs9X7arIy243bVm_2_NarD_WrM6U38BJ_WOIQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1770799243</pqid></control><display><type>article</type><title>High dose frusemide in the treatment of hypertension in chronic renal insufficiency and of terminal renal failure</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Rastogi, S. P. ; Volans, G. ; Elliott, R. W. ; Eccleston, D. W. ; Ashcroft, R. ; Webster, D. ; Kerr, D. N. S.</creator><creatorcontrib>Rastogi, S. P. ; Volans, G. ; Elliott, R. W. ; Eccleston, D. W. ; Ashcroft, R. ; Webster, D. ; Kerr, D. N. S.</creatorcontrib><description>Frusemide in doses up to 2000 mg per day orally has proved a useful adjuvant therapy for resistant hypertension in patients with chronic renal failure, A worth-while diuresis is uncommon if the creatinine clearance is below 2 ml per minute but a useful, though often temporary, effect is obtained in the range 2 to 4 ml/min. Above this level of renal function the extent of the diuresis is not reliably predictable from the creatinine clearance but must be found individually for each patient. The dose should be increased with particular caution in patients with chronic pyelonephritis and a creatinine clearance above 10 ml per minute. Side-effects, other than those of excessive diuresis, have been uncommon. Hypokalaemia is readily prevented by the administration of potassium supplements and spironolactone. A rise in plasma urate is common but not usually dramatic and it has not precipitated secondary gout in our experience to date.</description><identifier>ISSN: 0032-5473</identifier><identifier>EISSN: 1469-0756</identifier><identifier>DOI: 10.1136/postgradmedj-47-suppl-45</identifier><identifier>PMID: 5579771</identifier><language>eng</language><publisher>England: The Fellowship of Postgraduate Medicine</publisher><subject>Adolescent ; Adult ; Creatine - blood ; Creatinine - metabolism ; Diuresis ; Female ; Furosemide - administration & dosage ; Furosemide - toxicity ; Gout ; Humans ; Hypertension, Renal - drug therapy ; Hypokalemia - prevention & control ; Kidney Failure, Chronic - drug therapy ; Male ; Metabolic Clearance Rate ; Methyldopa - therapeutic use ; Middle Aged ; Potassium - therapeutic use ; Pyelonephritis - drug therapy ; Sodium - blood ; Sodium - urine ; Spironolactone - therapeutic use ; Urea - blood ; Uric Acid - blood ; Urine - physiology</subject><ispartof>Postgraduate medical journal, 1971-04, Vol.47 (Suppl), p.45</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2012 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/5579771$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rastogi, S. P.</creatorcontrib><creatorcontrib>Volans, G.</creatorcontrib><creatorcontrib>Elliott, R. W.</creatorcontrib><creatorcontrib>Eccleston, D. W.</creatorcontrib><creatorcontrib>Ashcroft, R.</creatorcontrib><creatorcontrib>Webster, D.</creatorcontrib><creatorcontrib>Kerr, D. N. S.</creatorcontrib><title>High dose frusemide in the treatment of hypertension in chronic renal insufficiency and of terminal renal failure</title><title>Postgraduate medical journal</title><addtitle>Postgrad Med J</addtitle><description>Frusemide in doses up to 2000 mg per day orally has proved a useful adjuvant therapy for resistant hypertension in patients with chronic renal failure, A worth-while diuresis is uncommon if the creatinine clearance is below 2 ml per minute but a useful, though often temporary, effect is obtained in the range 2 to 4 ml/min. Above this level of renal function the extent of the diuresis is not reliably predictable from the creatinine clearance but must be found individually for each patient. The dose should be increased with particular caution in patients with chronic pyelonephritis and a creatinine clearance above 10 ml per minute. Side-effects, other than those of excessive diuresis, have been uncommon. Hypokalaemia is readily prevented by the administration of potassium supplements and spironolactone. A rise in plasma urate is common but not usually dramatic and it has not precipitated secondary gout in our experience to date.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Creatine - blood</subject><subject>Creatinine - metabolism</subject><subject>Diuresis</subject><subject>Female</subject><subject>Furosemide - administration & dosage</subject><subject>Furosemide - toxicity</subject><subject>Gout</subject><subject>Humans</subject><subject>Hypertension, Renal - drug therapy</subject><subject>Hypokalemia - prevention & control</subject><subject>Kidney Failure, Chronic - drug therapy</subject><subject>Male</subject><subject>Metabolic Clearance Rate</subject><subject>Methyldopa - therapeutic use</subject><subject>Middle Aged</subject><subject>Potassium - therapeutic use</subject><subject>Pyelonephritis - drug therapy</subject><subject>Sodium - blood</subject><subject>Sodium - urine</subject><subject>Spironolactone - therapeutic use</subject><subject>Urea - blood</subject><subject>Uric Acid - blood</subject><subject>Urine - physiology</subject><issn>0032-5473</issn><issn>1469-0756</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1971</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpNkUtv2zAQhIkiReIm_QkBCOTMli9xpWNiJHHRJD3kcSUoaRXTsR4mKSD-95Vrw-hpgZ1vF4MZQqjgP4RQ5ufQx_QeXN1ivWIaWByHYc109oXMhDYF45CZEzLjXEmWaVBn5FuMK86FAi1OyWmWQQEgZmSz8O9LWvcRaRPGiK2vkfqOpiXSFNClFrtE-4YutwOGhF30fbcDqmXoO1_RgJ1bT4s4No2vPHbVlrqu3p0kDK3fqXumcX49BrwgXxu3jvj9MM_J693ty3zBHv7c_5pfP7BSCZOYw1JKxXmFhdAghdaTe4EcVSHL3Dgtc8hdrZTUDc81NwawKSthTAVOFlqdk6v93yH0mxFjsqt-DJORaAUAh6KQWk3U5YEayylMOwTfurC1h4Amne11HxN-HmUXPqwBBZl9epvb58W9eOOPN_b3xKs9X7arIy243bVm_2_NarD_WrM6U38BJ_WOIQ</recordid><startdate>197104</startdate><enddate>197104</enddate><creator>Rastogi, S. P.</creator><creator>Volans, G.</creator><creator>Elliott, R. W.</creator><creator>Eccleston, D. W.</creator><creator>Ashcroft, R.</creator><creator>Webster, D.</creator><creator>Kerr, D. N. S.</creator><general>The Fellowship of Postgraduate Medicine</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>197104</creationdate><title>High dose frusemide in the treatment of hypertension in chronic renal insufficiency and of terminal renal failure</title><author>Rastogi, S. P. ; Volans, G. ; Elliott, R. W. ; Eccleston, D. W. ; Ashcroft, R. ; Webster, D. ; Kerr, D. N. S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b316t-aeb22300ce914721440011e0e392b86a42878ad3324f0840667efbc166c7a2943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1971</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Creatine - blood</topic><topic>Creatinine - metabolism</topic><topic>Diuresis</topic><topic>Female</topic><topic>Furosemide - administration & dosage</topic><topic>Furosemide - toxicity</topic><topic>Gout</topic><topic>Humans</topic><topic>Hypertension, Renal - drug therapy</topic><topic>Hypokalemia - prevention & control</topic><topic>Kidney Failure, Chronic - drug therapy</topic><topic>Male</topic><topic>Metabolic Clearance Rate</topic><topic>Methyldopa - therapeutic use</topic><topic>Middle Aged</topic><topic>Potassium - therapeutic use</topic><topic>Pyelonephritis - drug therapy</topic><topic>Sodium - blood</topic><topic>Sodium - urine</topic><topic>Spironolactone - therapeutic use</topic><topic>Urea - blood</topic><topic>Uric Acid - blood</topic><topic>Urine - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rastogi, S. P.</creatorcontrib><creatorcontrib>Volans, G.</creatorcontrib><creatorcontrib>Elliott, R. W.</creatorcontrib><creatorcontrib>Eccleston, D. W.</creatorcontrib><creatorcontrib>Ashcroft, R.</creatorcontrib><creatorcontrib>Webster, D.</creatorcontrib><creatorcontrib>Kerr, D. N. S.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Postgraduate medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rastogi, S. P.</au><au>Volans, G.</au><au>Elliott, R. W.</au><au>Eccleston, D. W.</au><au>Ashcroft, R.</au><au>Webster, D.</au><au>Kerr, D. N. S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High dose frusemide in the treatment of hypertension in chronic renal insufficiency and of terminal renal failure</atitle><jtitle>Postgraduate medical journal</jtitle><addtitle>Postgrad Med J</addtitle><date>1971-04</date><risdate>1971</risdate><volume>47</volume><issue>Suppl</issue><spage>45</spage><pages>45-</pages><issn>0032-5473</issn><eissn>1469-0756</eissn><abstract>Frusemide in doses up to 2000 mg per day orally has proved a useful adjuvant therapy for resistant hypertension in patients with chronic renal failure, A worth-while diuresis is uncommon if the creatinine clearance is below 2 ml per minute but a useful, though often temporary, effect is obtained in the range 2 to 4 ml/min. Above this level of renal function the extent of the diuresis is not reliably predictable from the creatinine clearance but must be found individually for each patient. The dose should be increased with particular caution in patients with chronic pyelonephritis and a creatinine clearance above 10 ml per minute. Side-effects, other than those of excessive diuresis, have been uncommon. Hypokalaemia is readily prevented by the administration of potassium supplements and spironolactone. A rise in plasma urate is common but not usually dramatic and it has not precipitated secondary gout in our experience to date.</abstract><cop>England</cop><pub>The Fellowship of Postgraduate Medicine</pub><pmid>5579771</pmid><doi>10.1136/postgradmedj-47-suppl-45</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0032-5473 |
ispartof | Postgraduate medical journal, 1971-04, Vol.47 (Suppl), p.45 |
issn | 0032-5473 1469-0756 |
language | eng |
recordid | cdi_proquest_journals_1770799243 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
subjects | Adolescent Adult Creatine - blood Creatinine - metabolism Diuresis Female Furosemide - administration & dosage Furosemide - toxicity Gout Humans Hypertension, Renal - drug therapy Hypokalemia - prevention & control Kidney Failure, Chronic - drug therapy Male Metabolic Clearance Rate Methyldopa - therapeutic use Middle Aged Potassium - therapeutic use Pyelonephritis - drug therapy Sodium - blood Sodium - urine Spironolactone - therapeutic use Urea - blood Uric Acid - blood Urine - physiology |
title | High dose frusemide in the treatment of hypertension in chronic renal insufficiency and of terminal renal failure |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T08%3A39%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20dose%20frusemide%20in%20the%20treatment%20of%20hypertension%20in%20chronic%20renal%20insufficiency%20and%20of%20terminal%20renal%20failure&rft.jtitle=Postgraduate%20medical%20journal&rft.au=Rastogi,%20S.%20P.&rft.date=1971-04&rft.volume=47&rft.issue=Suppl&rft.spage=45&rft.pages=45-&rft.issn=0032-5473&rft.eissn=1469-0756&rft_id=info:doi/10.1136/postgradmedj-47-suppl-45&rft_dat=%3Cproquest_pubme%3E3972196001%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1770799243&rft_id=info:pmid/5579771&rfr_iscdi=true |